{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06469164",
            "orgStudyIdInfo": {
                "id": "BNT331-01"
            },
            "organization": {
                "fullName": "BioNTech SE",
                "class": "INDUSTRY"
            },
            "briefTitle": "A First-in-human Safety Trial of BNT331 Administered as Single Ascending Doses in Healthy Women and as Multiple Ascending Doses in Women Diagnosed With Bacterial Vaginosis",
            "officialTitle": "A Phase I Randomized, Double-blind, Placebo-controlled, Safety, Tolerability, and Pharmacokinetic Trial of BNT331 Administered in Single Ascending Doses in Healthy Women and Multiple Ascending Doses in Women Diagnosed With Bacterial Vaginosis",
            "therapeuticArea": [
                "Infectious Diseases"
            ],
            "study": "a-first-in-human-safety-trial-of-administered-as-single-ascending-doses-in-healthy-women-and-as-multiple-ascending-doses-in-women-diagnosed-with-bacterial-vaginosis"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-07",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-07-01",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-05",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2025-05",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2024-06-17",
            "studyFirstSubmitQcDate": "2024-06-17",
            "studyFirstPostDateStruct": {
                "date": "2024-06-21",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-03",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-05",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "BioNTech SE",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "This is a two-part, randomized, double-blind, placebo-controlled study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy (for Part B) of BNT331 in healthy women (Part A) and in women diagnosed with bacterial vaginosis (BV) (Part B).",
            "detailedDescription": "Part A will include single ascending dose levels and will assess the safety of BNT331 and describe the incidence of adverse events (AEs) for participants randomized at a ratio of 3:1 to BNT331 or placebo. Participants will receive one single dose of study treatment.\n\nPart B will include multiple ascending dose levels. Participants will be randomized at a ratio of 2:1 to BNT331 or placebo. Participants with BV will receive study treatment for five consecutive days.\n\nThe vaginal inserts will be self-administered by the participant. The participants will receive detailed instructions from the investigator on how to self-administer the vaginal inserts at home."
        },
        "conditionsModule": {
            "conditions": [
                "Bacterial Vaginosis"
            ],
            "keywords": [
                "Gardnerella spp.",
                "Gardnerella vaginalis",
                "BNT331"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "SEQUENTIAL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "QUADRUPLE",
                    "maskingDescription": "Observer-blind",
                    "whoMasked": [
                        "PARTICIPANT",
                        "CARE_PROVIDER",
                        "INVESTIGATOR",
                        "OUTCOMES_ASSESSOR"
                    ]
                }
            },
            "enrollmentInfo": {
                "count": 96,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "BNT331 - Part A",
                    "type": "EXPERIMENTAL",
                    "description": "Single ascending dose levels",
                    "interventionNames": [
                        "Drug: BNT331"
                    ]
                },
                {
                    "label": "Placebo - Part A",
                    "type": "PLACEBO_COMPARATOR",
                    "description": "Single dose",
                    "interventionNames": [
                        "Other: Placebo"
                    ]
                },
                {
                    "label": "BNT331 - Part B Dose 1",
                    "type": "EXPERIMENTAL",
                    "description": "Fixed dose for 5 consecutive days",
                    "interventionNames": [
                        "Drug: BNT331"
                    ]
                },
                {
                    "label": "BNT331 - Part B Dose 2",
                    "type": "EXPERIMENTAL",
                    "description": "Fixed dose for 5 consecutive days",
                    "interventionNames": [
                        "Drug: BNT331"
                    ]
                },
                {
                    "label": "Placebo - Part B",
                    "type": "PLACEBO_COMPARATOR",
                    "description": "Multiple dose",
                    "interventionNames": [
                        "Other: Placebo"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "BNT331",
                    "description": "Vaginal insert",
                    "armGroupLabels": [
                        "BNT331 - Part A",
                        "BNT331 - Part B Dose 1",
                        "BNT331 - Part B Dose 2"
                    ]
                },
                {
                    "type": "OTHER",
                    "name": "Placebo",
                    "description": "Vaginal insert",
                    "armGroupLabels": [
                        "Placebo - Part A",
                        "Placebo - Part B"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Part A - Percentage of participants with adverse events (AEs) with onset after first treatment dose and until the Follow-up Visit",
                    "description": "In participants who have received at least one dose of BNT331 or placebo. For each dose level cohort of BNT331 and for the combined placebo group.",
                    "timeFrame": "from first dose of study treatment up to 12 days post-dose"
                },
                {
                    "measure": "Part B - Percentage of participants with adverse events (AEs) with onset after first treatment dose and until Late Follow-up Visit",
                    "description": "In participants who have received at least one dose of BNT331 or placebo. For each dose level cohort of BNT331 and for the combined placebo group.",
                    "timeFrame": "from first dose of study treatment up to 127 days post-first dose"
                },
                {
                    "measure": "Part A - Percentage of participants with serious adverse events (SAEs) with onset after first treatment dose and until the Follow-up Visit",
                    "description": "In participants who have received at least one dose of BNT331 or placebo. For each dose level cohort of BNT331 and for the combined placebo group.",
                    "timeFrame": "from first dose of study treatment up to 12 days post-dose"
                },
                {
                    "measure": "Part B - Percentage of participants with SAEs with onset after first treatment dose and until the Late Follow-up Visit",
                    "description": "In participants who have received at least one dose of BNT331 or placebo. For each dose level cohort of BNT331 and for the combined placebo group.",
                    "timeFrame": "from first dose of study treatment up to 127 days post-first dose"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Part A - Serum concentrations of BNT331 active substance at pre-specified timepoints",
                    "description": "For each dose level cohort of BNT331. In participants who received one single administration.",
                    "timeFrame": "from pre-dose up to 12 days post-dose"
                },
                {
                    "measure": "Part B - Serum concentrations of BNT331 active substance at pre-specified timepoints",
                    "description": "For each dose level cohort of BNT331. In participants who received all scheduled administrations.",
                    "timeFrame": "from pre-dose up to 30 days post-first dose"
                },
                {
                    "measure": "Part A - Anti-drug antibody (ADA) prevalence or change of binding titers against BNT331 active substance in blood before study treatment and at the Follow-up Visit",
                    "description": "For each dose level cohort of BNT331",
                    "timeFrame": "from pre-dose up to 12 days post-dose"
                },
                {
                    "measure": "Part B - ADA prevalence or change of binding titers against BNT331 active substance in blood before study treatment and at the Test of Cure (ToC) Visit",
                    "description": "For each dose level cohort of BNT331",
                    "timeFrame": "from pre-dose up to 30 days post-first dose"
                },
                {
                    "measure": "Part B - Number of participants with clinical cure",
                    "description": "For each dose level cohort of BNT331 and for the combined placebo group. Normalization of the vaginal discharge, a negative potassium hydroxide (KOH) \"Whiff\" test, and clue cells \\<20% of the total epithelial cells/high power field on microscopic examination of the vaginal fluid.",
                    "timeFrame": "from 6 days post-first dose up to 30 days post-first dose"
                },
                {
                    "measure": "Part B - Number of participants with Nugent score cure/Microbiological cure",
                    "description": "For each dose level cohort of BNT331 and for the combined placebo group. Nugent score of \\<4.",
                    "timeFrame": "from 6 days post-first dose up to 30 days post-first dose"
                },
                {
                    "measure": "Part B - Responder outcome - Number of participants with clinical cure and normal Nugent score of <4",
                    "description": "For each dose level cohort of BNT331 and for the combined placebo group.",
                    "timeFrame": "from 6 days post-first dose up to 30 days post-first dose"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Have given written informed consent by signing and dating the informed consent form (ICF) before initiation of any study-specific procedures.\n* Participant reported assigned female sex at birth, at least 18 years of age and pre-menopausal, as determined by the investigator.\n* Not menstruating or having vaginal bleeding:\n\n  * Part A and Part B: At Visit 0 and Visit 1 and do not expect to menstruate within the study period.\n  * Part B only: At Visit 0 and Visit 1 and do not expect to menstruate within the next 6 days, until the Early Response Visit (Visit 2).\n* Part A only: Are healthy according to screening procedures. Part B only: Participants suffering from BV but who are otherwise healthy in the clinical judgement of the investigator.\n\n  * Note: Participants with pre-existing stable disease (e.g., obesity, hypertension, etc.), defined as disease not requiring significant change in therapy or hospitalization for worsening disease during the 90 days before Visit 0, can be included.\n* Part A only: Should not have any clinical signs of BV as assessed by the absence of all Amsel's criteria and a normal Nugent score at screening, or other vaginal symptoms, including symptomatic vulvo-vaginal candidiasis (VVC) or infection with sexually transmitted infection (STI) pathogens including Chlamydia trachomatis, Trichomonas vaginalis, or Neisseria gonorrhoeae.\n* Able to participate in the study as an outpatient, to attend all required visits, and to comply with all study requirements.\n* Women of childbearing potential must have a negative highly sensitive urine pregnancy test result prior to study treatment initiation.\n* The participant must have been on the same form of highly effective contraception for at least 3 months prior to dosing (Visit 1) and must agree to keep this method until:\n\n  * Part A: 60 days after Follow-up Visit (Visit 3)\n  * Part B: at least 60 days after Test of Cure (ToC) Visit (Visit 3).\n* Women of childbearing potential who agree not to donate or cryopreserve eggs (ova, oocytes) for the purposes of assisted reproduction during study:\n\n  * Part A: Within 3 months prior to dosing (Visit 1) and continuously until 60 days after Follow-up Visit (Visit 3)\n  * Part B: Starting at Visit 0 and continuously until the Late Follow-up Visit (Visit 5).\n* Agree to abstain from vaginal intercourse until:\n\n  * Part A: The Follow-up Visit (Visit 3)\n  * Part B: For the duration of treatment (\\~5 days) and until ToC Visit (Visit 3).\n* Agree to not use any vaginal products, e.g., creams, gels, foams, sponges, douches, and tampons (except during menstruation), until:\n\n  * Part A: The Follow-up Visit (Visit 3)\n  * Part B: ToC Visit (Visit 3).\n* Part B only: Have a clinical diagnosis of BV, defined as having all the following Amsel's criteria (4/4):\n\n  1. Off-white (milky or gray), thin, homogeneous vaginal discharge.\n  2. Vaginal pH \\>4.5.\n  3. Presence of clue cells \u226520% of the total epithelial cells/high power field on microscopic examination of the vaginal saline wet mount.\n  4. A positive 10% KOH Whiff test.\n* Part B only: Have a sample collected within 72 h prior to first dose for a Gram stain slide to assess Nugent score by the central laboratory.\n\nExclusion Criteria:\n\n* Pregnant, lactating, or planning to become pregnant during their study participation and for at least:\n\n  * Part A: 60 days after Follow-up Visit (Visit 3)\n  * Part B: 60 days after ToC Visit (Visit 3).\n* Have genital lesions, including active herpes simplex virus or syphilitic lesions, or other vaginal or vulvar conditions.\n* Part A only: Have active STI.\n* Had received antifungal or antimicrobial therapy (in Part A, systemic or topical; in Part B, systemic or vaginal) within 14 days prior to the Visit 1.\n* Are using a Copper intrauterine device, or any vaginal hormonal products (including NuvaRing\u00ae) as a form of contraception.\n* Had a history of drug or alcohol abuse within the past 12 months, as determined by the investigator.\n* Had participated in any investigational study within 30 days before the Visit 1 or is currently participating or plans to participate in any investigational, or observational study.\n* Has any history of allergies, hypersensitivities, or intolerance to the study treatments including any excipients thereof.\n* Has any history of an abnormal Pap smear which required cervical biopsy and/or cervical cauterization within 6 months of Visit 1\n* Malignancy within 5 years of screening, including but not limited to cervical carcinoma and carcinomas of the vagina and vulva.\n* Has any condition including psychiatric illnesses that could interfere with their ability to understand or comply with the requirements of the study as determined by the investigator.\n* Part B only: Currently suspected clinically (or confirmed diagnostically) of having alternative causes of vaginal disease symptoms including symptomatic VVC or infection with STI including Chlamydia trachomatis, Trichomonas vaginalis, or Neisseria gonorrhoeae.",
            "healthyVolunteers": true,
            "sex": "FEMALE",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "BioNTech clinical trials patient information",
                    "role": "CONTACT",
                    "phone": "+49 6131 9084",
                    "phoneExt": "0",
                    "email": "patients@biontech.de"
                }
            ],
            "overallOfficials": [
                {
                    "name": "BioNTech Responsible Person",
                    "affiliation": "BioNTech SE",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "UAB Sexual Health Research Clinic",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Birmingham",
                    "state": "Alabama",
                    "zip": "35294-0007",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 33.52066,
                        "lon": -86.80249
                    }
                },
                {
                    "facility": "Praetorian Pharmaceutical Research, LLC",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Marrero",
                    "state": "Louisiana",
                    "zip": "70072",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 29.89937,
                        "lon": -90.10035
                    }
                },
                {
                    "facility": "Southern Clinical Research Associates - Metairie",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Metairie",
                    "state": "Louisiana",
                    "zip": "70001",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 29.98409,
                        "lon": -90.15285
                    }
                },
                {
                    "facility": "Women Under Study, LLC",
                    "status": "NOT_YET_RECRUITING",
                    "city": "New Orleans",
                    "state": "Louisiana",
                    "zip": "70125",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 29.95465,
                        "lon": -90.07507
                    }
                },
                {
                    "facility": "Nucleus Network",
                    "status": "RECRUITING",
                    "city": "Saint Paul",
                    "state": "Minnesota",
                    "zip": "55114",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 44.94441,
                        "lon": -93.09327
                    }
                },
                {
                    "facility": "Velocity clinical Resesarch, Norfolk",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Norfolk",
                    "state": "Nebraska",
                    "zip": "68701",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 42.02834,
                        "lon": -97.417
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000016585",
                    "term": "Vaginosis, Bacterial"
                },
                {
                    "id": "D000014623",
                    "term": "Vaginal Diseases"
                }
            ],
            "ancestors": [
                {
                    "id": "D000005831",
                    "term": "Genital Diseases, Female"
                },
                {
                    "id": "D000052776",
                    "term": "Female Urogenital Diseases"
                },
                {
                    "id": "D000005261",
                    "term": "Female Urogenital Diseases and Pregnancy Complications"
                },
                {
                    "id": "D000091642",
                    "term": "Urogenital Diseases"
                },
                {
                    "id": "D000091662",
                    "term": "Genital Diseases"
                },
                {
                    "id": "D000001424",
                    "term": "Bacterial Infections"
                },
                {
                    "id": "D000001423",
                    "term": "Bacterial Infections and Mycoses"
                },
                {
                    "id": "D000007239",
                    "term": "Infections"
                },
                {
                    "id": "D000014627",
                    "term": "Vaginitis"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M17371",
                    "name": "Vaginal Diseases",
                    "asFound": "Vaginosis",
                    "relevance": "HIGH"
                },
                {
                    "id": "M18971",
                    "name": "Vaginosis, Bacterial",
                    "asFound": "Bacterial Vaginosis",
                    "relevance": "HIGH"
                },
                {
                    "id": "M8943",
                    "name": "Genital Diseases, Female",
                    "relevance": "LOW"
                },
                {
                    "id": "M2876",
                    "name": "Genital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M2875",
                    "name": "Urogenital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M27093",
                    "name": "Female Urogenital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M14127",
                    "name": "Pregnancy Complications",
                    "relevance": "LOW"
                },
                {
                    "id": "M8399",
                    "name": "Female Urogenital Diseases and Pregnancy Complications",
                    "relevance": "LOW"
                },
                {
                    "id": "M10283",
                    "name": "Infections",
                    "relevance": "LOW"
                },
                {
                    "id": "M6368",
                    "name": "Communicable Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M4722",
                    "name": "Bacterial Infections",
                    "relevance": "LOW"
                },
                {
                    "id": "M12136",
                    "name": "Mycoses",
                    "relevance": "LOW"
                },
                {
                    "id": "M4721",
                    "name": "Bacterial Infections and Mycoses",
                    "relevance": "LOW"
                },
                {
                    "id": "M17375",
                    "name": "Vaginitis",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BXS",
                    "name": "Urinary Tract, Sexual Organs, and Pregnancy Conditions"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC01",
                    "name": "Infections"
                },
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                }
            ]
        }
    },
    "hasResults": false
}